Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ANIL K SOOD and GEORGE A CALIN.
ANIL K SOOD
Connection Strength
2.436
GEORGE A CALIN
  1. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2020 06 03; 11(1):2867.
    View in: PubMed
    Score: 0.182
  2. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 06 01; 23(11):2891-2904.
    View in: PubMed
    Score: 0.143
  3. microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine. 2016 Oct; 12:34-42.
    View in: PubMed
    Score: 0.141
  4. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016 Mar; 6(3):235-46.
    View in: PubMed
    Score: 0.135
  5. Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. Methods Mol Biol. 2016; 1402:33-41.
    View in: PubMed
    Score: 0.134
  6. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec 22; 13(11):2395-2402.
    View in: PubMed
    Score: 0.134
  7. Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. Noncoding RNA. 2015 Jun 03; 1(1):53-68.
    View in: PubMed
    Score: 0.129
  8. Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun. 2014 Oct 29; 5:5202.
    View in: PubMed
    Score: 0.124
  9. RNAi therapies: drugging the undruggable. Sci Transl Med. 2014 Jun 11; 6(240):240ps7.
    View in: PubMed
    Score: 0.120
  10. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov. 2013 Nov; 3(11):1302-15.
    View in: PubMed
    Score: 0.114
  11. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.109
  12. MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011 Jun 07; 8(8):467-77.
    View in: PubMed
    Score: 0.098
  13. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.
    View in: PubMed
    Score: 0.095
  14. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97.
    View in: PubMed
    Score: 0.092
  15. Corrigendum to Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2024 Dec 04; 111:105486.
    View in: PubMed
    Score: 0.062
  16. Author Correction: Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2023 Nov 08; 9(1):111.
    View in: PubMed
    Score: 0.058
  17. CORRIGENDUM: GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2022 Jan; 89:110147.
    View in: PubMed
    Score: 0.050
  18. Corrigendum to 'Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer' [EBioMedicine 38 (2018) 100-112]. EBioMedicine. 2020 Feb; 52:102630.
    View in: PubMed
    Score: 0.044
  19. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. Cell Signal. 2020 04; 68:109539.
    View in: PubMed
    Score: 0.044
  20. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol. 2020 11; 17(11):1523-1534.
    View in: PubMed
    Score: 0.044
  21. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018 Dec; 38:100-112.
    View in: PubMed
    Score: 0.041
  22. A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. Nat Commun. 2018 01 31; 9(1):461.
    View in: PubMed
    Score: 0.039
  23. Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov. 2017; 3:17029.
    View in: PubMed
    Score: 0.038
  24. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 2017 Mar 21; 8(12):20145-20164.
    View in: PubMed
    Score: 0.037
  25. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 2016 12 15; 76(24):7194-7207.
    View in: PubMed
    Score: 0.035
  26. Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. Cell Rep. 2016 05 17; 15(7):1493-1504.
    View in: PubMed
    Score: 0.034
  27. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.034
  28. The ZNF304-integrin axis protects against anoikis in cancer. Nat Commun. 2015 Jun 17; 6:7351.
    View in: PubMed
    Score: 0.032
  29. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. 2015 Mar; 17(3):311-21.
    View in: PubMed
    Score: 0.032
  30. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 01; 21(9):2127-37.
    View in: PubMed
    Score: 0.031
  31. A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. EMBO J. 2013 Oct 30; 32(21):2833-47.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.